📈 Jumpstart Signal Watchlist — August 19, 2026

🏢 What they do: Mitek Systems, Inc. (MITK) specializes in digital identity verification, authentication, biometrics, mobile image capture, and fraud detection solutions. Its enterprise-grade platform enables secure onboarding, check deposits, transaction protection, and real-time defense against threats like deepfakes and synthetic fraud for banks, fintechs, and other organizations.
- 🎯 Current $18.88 is 6% below 3yr high $20.14 · ⏳ SMA200 $13.71 (current price $18.88 is above) · 💰 Market Cap $852M
- MITK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 240% (>20%); Revenue growth 18% (>15%); Low LT D/E 0.20 (<1.0); PEG ratio 0.17 (<1.5).
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Mitek Systems (NASDAQ:MITK) Shares Gap Up After Better Than Expected Earnings — MarketBeat.
🤖 Mitek reported quarterly EPS of $0.34 versus the $0.28 consensus and revenue of $54.04 million versus $50.82 million expected, which supported a sharp share-price move higher. The article is favorable for MITK because it highlights an earnings beat and a positive market reaction.
✅ Mitek Systems (NASDAQ:MITK) Upgraded by Wall Street Zen to "Strong-Buy" Rating — MarketBeat.
🤖 Wall Street Zen raised Mitek to Strong-Buy after the company’s quarterly results beat expectations, with the article also noting the stock rose about 10%. The upgrade and upbeat earnings context are constructive for the stock.
⚪️ Mitek Systems (NASDAQ:MITK) Stock Crosses Above 200-Day Moving Average - Here's What Happened — MarketBeat.
🤖 The stock moved above its 200-day moving average after the company’s recent strong quarterly results. This is mixed for MITK because it reflects improved momentum, but the piece is mainly a technical trading note rather than new business information.
🍭 Bonus (B): 10/10 — Computer Peripheral Equipment (Technology sector)

🏢 What they do: DiamondRock Hospitality Company (DRH) is a self-advised real estate investment trust (REIT) that owns a portfolio of approximately 35-36 premium hotels and resorts with about 9,600 rooms, concentrated in U.S. gateway markets and leisure destinations.
- 🎯 Current $12.72 is 5% below 3yr high $13.38 · ⏳ SMA200 $10.28 (current price $12.72 is above) · 💰 Market Cap $2.6B
- DRH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (10.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 144% (>20%); Low LT D/E 0.72 (<1.0); PEG ratio 0.12 (<1.5).
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ DiamondRock Hospitality Company Reports Second Quarter 2026 Results — PR Newswire.
🤖 DiamondRock reported second-quarter 2026 results and raised its quarterly common dividend by 22% to $0.11 per share. The earnings beat and higher dividend are constructive for the stock.
✅ DiamondRock Hospitality (NYSE:DRH) Given New $13.25 Price Target at Stifel Nicolaus — MarketBeat.
🤖 Stifel Nicolaus raised its price target on DRH to $13.25 while maintaining a Hold rating, and the stock traded near 52-week highs afterward. A higher target from a major brokerage is a modest positive signal.
⚪️ DiamondRock Hospitality Company (NYSE:DRH) Receives Consensus Recommendation of Hold from Analysts — MarketBeat.
🤖 MarketBeat reported that DRH’s analyst coverage remained at a consensus Hold, with an average price target around $12.03. The note is mixed rather than clearly bullish or bearish because it mainly reflects stable sentiment and target updates.
⚪️ DiamondRock Hospitality Company (NYSE:DRH) Receives Consensus Recommendation of Hold from Analysts — MarketBeat.
🤖 This update says the consensus analyst view stayed at Hold, with seven hold ratings and four buy ratings. It does not add a clearly directional catalyst for the stock.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $14.68 is 4% below 3yr high $15.26 · ⏳ SMA200 $9.25 (current price $14.68 is above) · 💰 Market Cap $992M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (8.8%)
- 🔔 Strong above EMA50 (20.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says — MarketBeat.
🤖 Canaccord Genuity raised its price target to $19 from $15 and kept a buy rating, reinforcing a bullish analyst view on BVS. The piece also notes strong recent earnings and a broader favorable consensus, which is supportive for the stock.
✅ Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of Buy from Brokerages — MarketBeat.
🤖 The article says six covering firms give BVS a consensus Buy rating, with an average target above the current price. It also points to the company’s latest earnings and full-year guidance as supportive factors.
✅ Bioventus (NASDAQ:BVS) Sets New 12-Month High — MarketBeat.
🤖 BVS hit a new 52-week high after strong quarterly earnings that beat EPS expectations. The article frames the move as part of improving investor sentiment and favorable analyst coverage.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 Current $53.13 is 11% below 3yr high $59.82 · ⏳ SMA200 $31.26 (current price $53.13 is above) · 💰 Market Cap $70.3B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 47/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 154% (>20%); Revenue growth 40% (>15%); Low LT D/E 0.86 (<1.0); PEG ratio 0.32 (<1.5).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
- ⚠️ RSI reversing from overbought (53) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Hewlett Packard Enterprise's AI Networking Is Impressive, Even After The Rally — Seeking Alpha.
🤖 The article says HPE’s Q2 2026 results were exceptional, with revenue up 40% year over year, gross margin expansion, and strong free cash flow. It argues AI hardware demand and record backlog support the stock, though it also notes execution and supply-chain risks.
✅ HPE stock hits a 52-week high: Is it too late to buy after ... — Finance Yahoo / related market article.
🤖 The piece highlights HPE’s sharp year-to-date rally and fresh 52-week high after the Morgan Stanley upgrade. That combination of strong momentum and bullish analyst sentiment is favorable for the stock, even if valuation is getting stretched.
✅ Hewlett Packard Enterprise wins approval for DOJ settlement in Juniper deal — Seeking Alpha News.
🤖 Court approval of the DOJ settlement removes a major regulatory hurdle for HPE’s Juniper Networks acquisition. Clearing that obstacle is strategically positive because it reduces deal uncertainty and could strengthen HPE’s networking business.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)

🏢 What they do: Cass Information Systems, Inc. provides integrated payment and information management services, specializing in auditing, processing, and paying high-volume invoices for freight transportation, utilities, telecom, waste, cloud, and facilities expenses.
- 🎯 Current $56.70 is 3% below 3yr high $58.54 · ⏳ SMA200 $46.41 (current price $56.70 is above) · 💰 Market Cap $726M
- CASS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (7.4% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 23% (>20%); ROE 15% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (56) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Truckload linehaul rates rip higher in July, Cass says — finance.yahoo.com.
🤖 Cass’s July freight report showed truckload linehaul rates rising 2.3% from June and 8.6% year over year, with the increase described as the largest in four years. That suggests healthier pricing trends in a core business metric, which is constructive for the stock.
✅ Cass Information Systems (NASDAQ:CASS) Sets New 52-Week High - Still a Buy? — MarketBeat.
🤖 The stock hit a new 52-week high, reflecting strong recent market momentum. The article also notes continued analyst support and a quarterly dividend, which are supportive for investor sentiment.
❌ Cass Information Systems (NASDAQ:CASS) Lowered to "Hold" Rating by Zacks Research — MarketBeat.
🤖 Zacks Research downgraded Cass from strong buy to hold, which is a near-term negative signal for sentiment. The downgrade followed a quarter in which earnings and revenue came in below estimates, reinforcing concerns about valuation and execution.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $54.39 is 5% below 3yr high $57.10 · ⏳ SMA200 $46.54 (current price $54.39 is above) · 💰 Market Cap $13.5B
- EXEL shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 53 in healthy mid-range
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 2/10
- 🗞️ News sentiment is negative (mixed coverage).
✅ Stifel Nicolaus Issues Positive Forecast for Exelixis Stock Price — MarketBeat.
🤖 Stifel raised its price target on EXEL to $51 from $47, signaling improved analyst expectations after the earnings release. Even though the firm kept a Hold rating, the higher target is a mildly positive sign for the stock.
❌ Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update — Business Wire.
🤖 Exelixis reported Q2 2026 results on August 5, including total revenue of $628.7 million, but also lowered its 2026 revenue outlook. The revenue guide cut and after-hours stock weakness make this modestly negative for EXEL.
❌ Exelixis Q2 2026 slides: strong earnings, but NET slowdown cuts guidance — Investing.com.
🤖 This article says Exelixis beat EPS estimates but missed revenue expectations and reduced its full-year 2026 revenue guidance. The mixed results are overshadowed by the guidance cut, which is negative for the stock.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $34.77 is 2% below 3yr high $35.53 · ⏳ SMA200 $24.23 (current price $34.77 is above) · 💰 Market Cap $4.4B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (12.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (11.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance — Business Wire.
🤖 Concentra reported Q2 2026 results with revenue growth of 10.0%, net income growth of 46.5%, and Adjusted EBITDA growth of 22.5%, while also raising full-year 2026 guidance. The company also declared a cash dividend and outlined a planned leadership succession, all of which are supportive for the stock.
✅ Concentra Group Holdings Parent (NYSE:CON) Sets New 1-Year High - Here's Why — MarketBeat.
🤖 This article highlights the stock’s breakout to a new 52-week high after the company beat quarterly expectations and analysts remained broadly bullish. It is positive for $CON because it emphasizes strong fundamentals, raised targets, and continued momentum.
✅ Concentra Group Holdings Parent (NYSE:CON) Stock Price Expected to Rise, Wells Fargo Company Analyst Says — MarketBeat.
🤖 The piece focuses on upbeat analyst sentiment, with seven Buy ratings and one Hold rating and a Moderate Buy consensus. That kind of coverage is supportive for the stock because it reinforces expectations for upside.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: Aramark is a global provider of outsourced food services, facilities management, and uniform services to clients in education, healthcare, business, sports, leisure, and corrections sectors .
- 🎯 Current $59.78 is 4% below 3yr high $62.39 · ⏳ SMA200 $45.30 (current price $59.78 is above) · 💰 Market Cap $15.8B
- ARMK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (7.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 33% (>20%); Low LT D/E 0.00 (<1.0); PEG ratio 1.25 (<1.5).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Aramark beats fiscal Q3 estimates as revenue growth ... — Yahoo Finance.
🤖 Aramark reported adjusted EPS of $0.52, ahead of the $0.48 consensus, alongside revenue growth in its fiscal third quarter. The earnings beat and stronger-than-expected operating performance are positive for the stock.
✅ Aramark (ARMK) Is Up 6.1% After Earnings Beat And ... — Yahoo Finance.
🤖 This article highlights the company’s fiscal third-quarter beat, raised full-year outlook, dividend declaration, and a new long-term dining partnership. Those developments point to improving fundamentals and shareholder returns.
⚪️ Aramark Declares Quarterly Dividend - Yahoo Finance — Yahoo Finance.
🤖 Aramark approved a quarterly dividend of $0.12 per share payable in September. The dividend is supportive, but by itself it is a routine capital-return announcement with limited near-term price impact.
🍭 Bonus (B): 0/10 — Restaurants